PMC:7172841 / 4419-4725 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T28","span":{"begin":164,"end":167},"obj":"Body_part"},{"id":"T29","span":{"begin":179,"end":188},"obj":"Body_part"},{"id":"T30","span":{"begin":212,"end":220},"obj":"Body_part"},{"id":"T31","span":{"begin":259,"end":272},"obj":"Body_part"}],"attributes":[{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T49","span":{"begin":73,"end":76},"obj":"Disease"},{"id":"T50","span":{"begin":294,"end":305},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T34","span":{"begin":179,"end":188},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T35","span":{"begin":212,"end":220},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T36","span":{"begin":259,"end":272},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":168,"end":170},"obj":"Chemical"},{"id":"T23","span":{"begin":274,"end":276},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A24","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-sentences","denotations":[{"id":"T36","span":{"begin":0,"end":306},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":112,"end":132},"obj":"Phenotype"},{"id":"T25","span":{"begin":294,"end":305},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T115","span":{"begin":112,"end":118},"obj":"UBERON:0002405;GO:0006955"},{"id":"T116","span":{"begin":119,"end":132},"obj":"GO:0006955"},{"id":"T117","span":{"begin":150,"end":160},"obj":"GO:0010467"},{"id":"T118","span":{"begin":164,"end":167},"obj":"PR:000029150"},{"id":"T119","span":{"begin":174,"end":178},"obj":"PR:000001889"},{"id":"T120","span":{"begin":179,"end":188},"obj":"CL:0000576"},{"id":"T121","span":{"begin":212,"end":220},"obj":"CL:0000576"},{"id":"T122","span":{"begin":248,"end":258},"obj":"GO:0050663"},{"id":"T123","span":{"begin":259,"end":272},"obj":"PR:000001393"},{"id":"T124","span":{"begin":274,"end":278},"obj":"PR:000001393"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}

{"project":"LitCovid-PubTator","denotations":[{"id":"185","span":{"begin":174,"end":178},"obj":"Gene"},{"id":"186","span":{"begin":259,"end":272},"obj":"Gene"},{"id":"187","span":{"begin":274,"end":278},"obj":"Gene"},{"id":"191","span":{"begin":50,"end":58},"obj":"Species"},{"id":"192","span":{"begin":91,"end":99},"obj":"Species"},{"id":"201","span":{"begin":64,"end":67},"obj":"Disease"},{"id":"202","span":{"begin":294,"end":305},"obj":"Disease"}],"attributes":[{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"Gene:929"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"Gene:3569"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"Gene:3569"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"Tax:9606"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"Tax:9606"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:D008231"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Results revealed that approximately one fourth of patients with SRF have MAS and that most patients suffer from immune dysregulation dominated by low expression of HLA-DR on CD14 monocytes, which is triggered by monocyte hyperactivation, excessive release of interleukin-6 (IL-6), and profound lymphopenia."}